https://www.thebodypro.com/author/brian-a-boyle

Latest by Brian A. Boyle, M.D., J.D.

Promo Image
News

NNRTIs: The Next Generation Approaches (Part I)

Part I

Introduction Mechanisms of NNRTI Activity and HIV NNRTI Resistance NNRTI Resistance in NNRTI-Naive and NNRTI-Experienced Individuals NNRTI Mutations: Resistance and Cross-Resistance NRTI Mutations: The Potential Impact on NNRTIs NNR...

Promo Image

NNRTIs: The Next Generation Approaches (Part II)

Case Study: Patient JD

JD is a 46-year-old gay male. He first learned of his HIV status in 1994 after a former partner with whom he had been in a three-year relationship discovered that he was HIV infected.

JD felt well when he was first tested for...

Promo Image

ACTG 5095: Efavirenz-Based Regimens Outperform Triple Nucleoside Combination

ACTG 5095: A Comparative Study of Three Protease Inhibitor-Sparing Antiretroviral Regimens for the Initial Treatment of HIV Infection (Oral 41) Authored by R.M. Gulick, H.J. Ribaudo, C.M. Shikuma, S. Lustgarten, W.A. Meyer, K. Klingman, K.E. Sq...

Promo Image

Efavirenz-Based HAART Outperforms a Triple Nucleoside Regimen in Clinical Practice

An Observational Cohort Comparison of Zidovudine-Lamivudine-Efavirenz to Zidovudine-Lamivudine-Abacavir in Antiretroviral-Naive Individuals (Poster 554) Authored by N. Nassar, L. Armas, J. Smillie, S. Moreno, P. Keiser

The ACTG 5095 trial (for...

Promo Image
Neurocognitive

ACTG 5097s: Efavirenz-Related CNS Events in the 5095 Study

ACTG 5097s: Impact of Efavirenz (EFV) on Neuropsychological Performance, Mood and Sleep Behavior in HIV-Positive Individuals (Oral 54) Authored by D.B. Clifford, S. Evans, Y. Yang, E. Acosta, K. Goodkin, R.M. Gulick

One of the most eagerly awa...

Promo Image

Atazanavir: A Once-Daily Protease Inhibitor With a Superior Lipid Profile: Results of Clinical Trials Beyond Week 48

Atazanavir: A Once-Daily Protease Inhibitor With a Superior Lipid Profile: Results of Clinical Trials Beyond Week 48 Abstract 706-T Authored by P. Piliero1, P. Cahn2, G. Pantaleo3, J. M. Gatell4, K. Squires5, L. Percival6, I. Sanne7, R. Woo...

Promo Image

A Randomized Trial Comparing Two Four-Drug Antiretroviral Regimens With a Three-Drug Regimen in Advanced HIV Disease (Abstract 41)

A Randomized Trial Comparing Two Four-Drug Antiretroviral Regimens With a Three-Drug Regimen in Advanced HIV Disease Abstract 41 Authored by M. Fischl1, H. Ribaudo2, A. C. Collier3, A. Erice4, M. Giuliano5, M. Dehlinger6, J. J. Eron7, M. Sa...

Promo Image

Discontinuation of Maintenance Therapy for Cytomegalovirus Retinitis in HIV-Infected Patients Who Have Responded to Highly Active Antiretroviral Therapy

Discontinuation of Maintenance Therapy for Cytomegalovirus Retinitis in HIV-Infected Patients Who Have Responded to Highly Active Antiretroviral Therapy Abstract 1888 Authored by S. L. Walmsley (University of Toronto, Toronto, ON, Canada), ...

Promo Image

Once-Daily Atazanavir Plus Saquinavir Favorably Affects Total Cholesterol (TC) and Fasting Triglyceride (TG) Profiles in Patients Failing Prior PI Therapy (Trial AI424-009, Week 24)

Once-Daily Atazanavir Plus Saquinavir Favorably Affects Total Cholesterol (TC) and Fasting Triglyceride (TG) Profiles in Patients Failing Prior PI Therapy (Trial AI424-009, Week 24) Abstract LB-16 Authored by D. Haas (Vanderbilt Univ., Nash...

Promo Image

Effect of Food on Oral Bioavailability of Didanosine From Delayed Release Capsules Containing Enteric Coated Beads

Effect of Food on Oral Bioavailability of Didanosine from Delayed Release Capsules Containing Enteric Coated Beads Abstract 499 Authored by B. D. Damle, J.-H. Yan, D. Behr, E. O'mara, P. Nichola, S. Kaul, C. A. Knupp, (Bristol-Myers Squibb,...